1 hour ago
1
MICHELLE CHAPMAN
Wed, March 25, 2026 astatine 8:39 AM CDT 1 min read
Merck is buying oncology institution Terns Pharmaceuticals successful a woody valued astatine astir $6.7 cardinal arsenic the pharmaceutical elephantine works connected beefing up its crab portfolio earlier a cardinal patent connected its crab cause Keytruda expires successful 2 years.
Merck received accelerated support for Keytruda from the Food and Drug Administration successful September 2014 to dainty precocious oregon unresectable melanoma. The cause has since been approved to dainty much than 15 types of cancers and has been a cardinal contributor to Merck's revenue.
Terns of Foster City, California, is presently processing a cause to dainty definite patients with chronic myeloid leukemia, which is simply a dilatory increasing benignant of humor crab that leads to an overproduction of achromatic humor cells that accumulate successful the humor and bony marrow, disrupting the accumulation of steadfast humor cells.
A Merck subsidiary volition wage $53 per stock successful currency for each Terns share.
Terns' banal roseate much than 5% successful aboriginal trading Wednesday. Merck shares were up little than 1%.
Both companies' boards person approved the transaction, which is expected to adjacent successful the 2nd quarter. The woody is taxable to a bulk of Terns’ stockholders tendering their shares successful a tender connection that volition beryllium initiated by a Merck subsidiary.
Rahway, New Jersey-based Merck said it volition publication a complaint of astir $5.8 billion, oregon astir $2.35 per share, related to the acquisition successful its second-quarter and full-year results.
Last twelvemonth Merck announced that it was buying Verona Pharma, a institution that focuses connected respiratory diseases, successful an astir $10 cardinal deal.
English (CA) · 
English (US) · 
Spanish (MX) ·